The Strategic Integration of Qualifying Health Insurance Premium Expenditures within the Massachusetts Research and Development Tax Credit Framework

The Qualifying Health Insurance Premium Expenditure Credit is a specialized state-level incentive designed to assist small businesses in offsetting the costs of providing medical coverage, while in the specific context of the Massachusetts Research and Development (R&D) Tax Credit, these premium costs are treated as a component of “qualified wages” to augment the base for innovation-related tax offsets. Under Massachusetts Department of Revenue Directive 02-15, taxpayers are permitted to include employer-paid health insurance premiums as qualified research expenses (QREs), effectively increasing the value of the 10% incremental credit for scientific and technological activities conducted within the Commonwealth.

Theoretical and Legislative Foundations of the Massachusetts Innovation Economy

The intersection of healthcare policy and industrial innovation in Massachusetts represents one of the most sophisticated areas of regional fiscal law. To fully comprehend the meaning and application of the Qualifying Health Insurance Premium Expenditure (QHIPE) within the R&D tax credit framework, one must first analyze the broader economic landscape of the Commonwealth. Massachusetts has long positioned itself as a global leader in biotechnology, software engineering, and advanced manufacturing, sectors that are characterized by high labor costs and significant investments in human capital. The state’s tax code, specifically through M.G.L. c. 63, § 38M, serves as a primary mechanism to sustain this leadership by lowering the effective cost of research.

The Research Credit was established to mirror the federal research credit available under Internal Revenue Code (IRC) § 41, yet it has evolved to address specific regional priorities.1 Unlike the federal credit, which has faced periods of expiration and temporary extensions, the Massachusetts credit is a permanent fixture of the corporate excise law, providing the long-term certainty required for multi-year research initiatives.3 The inclusion of health insurance premiums as a “qualified expense” is a pivotal refinement of this law, rooted in the recognition that a researcher’s total compensation package—not just their base salary—constitutes the true investment in innovation.

The concept of a “Qualifying Health Insurance Premium Expenditure” arises from two distinct but interacting statutory paths. The first is found in M.G.L. c. 62, § 6(f) and c. 63, § 38X, which provide a direct credit for small businesses that provide health insurance to their employees.4 The second is found in the administrative guidance of Directive 02-15, which allows these same expenditures to be reclassified as “wages” for the purpose of the R&D credit calculation.6 This dual-track system creates a strategic choice for businesses: they may either claim a standalone credit for the premiums if they meet small-business size requirements or include the premiums in their R&D expense base to drive a larger innovation credit.

Detailed Analysis of Qualifying Health Insurance Premium Expenditures

The term “Qualifying Health Insurance Premium Expenditure” (QHIPE) refers to the total amount an employer pays toward health insurance premiums for its employees, provided that the insurance plan meets the Commonwealth’s standards for “Minimum Creditable Coverage” (MCC). In the Massachusetts regulatory environment, MCC is the baseline level of benefits that a resident must have to satisfy the state’s individual mandate.8 For an expenditure to be considered “qualifying” under the tax code, the employer must generally contribute at least 50% of the total cost of the premiums and the plan must be made available to all full-time employees.4

The meaning of this expenditure in the context of R&D is fundamentally about the definition of “wages.” Under federal law (IRC § 3401(a)), wages are defined broadly as remuneration for services performed by an employee. However, federal R&D credits often exclude certain fringe benefits from the definition of qualified wages. Massachusetts takes a more expansive view. Through Directive 02-15, the Department of Revenue (DOR) clarifies that health insurance premiums are a form of compensation for services rendered and thus should be includable in the wage component of the R&D credit.6

The Role of Minimum Creditable Coverage (MCC)

The eligibility of a health insurance premium expenditure is intrinsically linked to the quality of the insurance provided. The Massachusetts Health Connector defines MCC as a plan that provides a comprehensive set of services, including doctor visits, hospitalizations, and prescription drug coverage.8 Plans that have caps on total benefits for a particular illness or that do not provide maternity services are generally excluded from being MCC-compliant.12

For a business to leverage these expenditures in an R&D claim, the premiums must be paid toward a plan that satisfies these standards. This alignment ensures that the state is not only subsidizing innovation but also encouraging the provision of high-quality healthcare to the workers driving that innovation. Taxpayers are required to report their insurance status on Schedule HC, and employers must provide Form MA 1099-HC to employees, which serves as the primary evidence for the “qualifying” nature of the expenditure.9

Local State Revenue Office Guidance: Directive 02-15

The most critical document for practitioners and business owners is Department of Revenue Directive 02-15, titled “Massachusetts Research Credit: Wages Paid to Employees Performing Research Services and Health Insurance Premiums.” This directive provides the administrative bridge between the general R&D statute and the specific treatment of employee benefits.6

The Logic of Includability

The DOR’s reasoning in Directive 02-15 is based on the premise that the Research Credit should capture the full economic cost of research activities conducted within Massachusetts. When a scientist or engineer is hired to perform qualified research, the employer’s obligation includes not just the hourly rate or salary, but also the mandatory and voluntary benefits that facilitate that employment. By allowing the inclusion of health insurance premiums, the DOR effectively reduces the “all-in” cost of high-level technical labor.

The application of Directive 02-15 requires a precise allocation method. If an employee spends 100% of their time on qualified research projects, 100% of the employer-paid health insurance premium for that employee is classified as a Massachusetts Qualified Research Expense (QRE).6 However, in most corporate environments, researchers split their time between qualified research, administrative tasks, and non-qualified production activities. In such cases, the premiums must be prorated.

Proration and Geographic Nexus

The Massachusetts Research Credit is strictly limited to research activity conducted in Massachusetts.1 This creates a two-step proration process for health insurance premiums:

1. Activity Proration: Determine the percentage of an employee’s time spent on “qualified research” as defined by the four-part test (Technological in Nature, Permitted Purpose, Elimination of Uncertainty, and Process of Experimentation).13
2. Geographic Proration: Determine the portion of that research activity that took place within the Commonwealth. If an employee performs research in both a Massachusetts lab and a Rhode Island facility, only the Massachusetts-based portion of the premium is eligible.7

Directive 02-15 mandates that these allocations be based on actual time tracking or other reliable contemporaneous records. Estimates that are not supported by data are frequently challenged during Department of Revenue audits.

Application to the Law: M.G.L. c. 63, § 38M

The primary statute governing the Research Credit is M.G.L. c. 63, § 38M. This section provides the formulaic structure for the credit and sets the boundaries for its application. The credit is calculated as 10% of the difference between the current year’s QREs and a base amount, plus 15% of basic research payments.1

The Traditional Method vs. The Alternative Simplified Credit (ASC)

Taxpayers have two options for calculating their credit, and the inclusion of health insurance premiums affects each differently.17

The Traditional Method

This method relies on a historical “fixed-base ratio” and the average annual gross receipts for the preceding four years.16 For many established companies, the fixed-base ratio is determined by spending patterns from the 1980s, which can be difficult to document. If a company uses this method, it must ensure that health insurance premiums are included in both the current year QREs and the base period QREs to satisfy the “consistency requirement” of the law.17

The Alternative Simplified Credit (ASC)

Introduced for tax years beginning on or after January 1, 2015, the ASC method is modeled after the federal alternative simplified credit.3 The ASC does not use gross receipts; instead, it uses a three-year rolling average of QREs. The credit is equal to 10% of the amount by which the current year’s QREs exceed 50% of the average QREs for the three preceding years.1

For businesses utilizing the ASC, the inclusion of health insurance premiums under Directive 02-15 is often more beneficial because it only requires looking back three years to find the corresponding benefit costs, rather than decades. The ASC rate was phased in over several years:

The full 10% rate now available under the ASC makes the inclusion of high-cost items like health insurance premiums particularly lucrative for research-heavy firms.2

The Regulatory Framework of § 38W and Life Sciences

The Massachusetts Life Sciences Center (MLSC) administers additional incentives that intersect with the R&D credit. Certified life sciences companies have access to a suite of benefits that are not available to general business corporations.19

Refundability for Life Sciences

The standard § 38M credit is nonrefundable for most corporations; it can only be used to offset excise tax liability, with any excess carried forward for up to 15 years.1 However, for certified life sciences companies, the credit can be made refundable.1

• Mechanism: If a certified company’s research credit exceeds its tax liability, it can elect to receive a refund equal to 90% of the remaining balance of the credit.13
• Approval: This requires specific authorization from the MLSC as part of their Tax Incentive Program, which opens for applications annually in December or January.19

The Separate § 38W Credit

There is also a separate Life Sciences Research Credit under M.G.L. c. 63, § 38W. This credit is designed for expenditures that might not qualify for the standard § 38M credit. Specifically, § 38W allows for the inclusion of expenses related to legally mandated clinical trial activities, even if those activities are performed outside of Massachusetts.18 While Directive 02-15 specifically addresses § 38M, the principles of including health insurance premiums as a component of research-related labor costs are generally applied across both credits to ensure consistent treatment of life sciences personnel.

Integrated Example: Calculating the Credit with Premium Expenditures

To illustrate the practical application of the QHIPE and Directive 02-15, consider the following case study of “TechNexus Inc.,” a Massachusetts biotechnology firm with 45 employees.

Financial Profile for 2024

TechNexus Inc. conducts all its research in a laboratory in Cambridge, MA. For the 2024 tax year, their expenses were:

• Salaries for Research Scientists: $5,000,000 (100% time spent on qualified R&D)
• Employer-Paid Health Insurance Premiums: $800,000 (for research staff)
• Prior 3-Year Average QREs: $4,200,000 (inclusive of salaries and premiums)

Step 1: Determine Massachusetts QREs

Without Directive 02-15, the company might only claim the base salaries:

$$QREs_{Salary} = \$5,000,000$$

With Directive 02-15, the company includes the health insurance premiums as qualified wages:

$$QREs_{Total} = \$5,000,000 + \$800,000 = \$5,800,000$$

Step 2: Calculate the Credit using the ASC Method

The company elects the ASC method for its 2024 return.

1. Current Year QREs: $5,800,000
2. Base Amount: 50% of the 3-year average ($4,200,000) = $2,100,000
3. Incremental Excess: $5,800,000 – $2,100,000 = $3,700,000
4. Credit Calculation: 10% of $3,700,000 = $370,000

Comparison Analysis: Had the company failed to include the $800,000 in health insurance premiums, their credit would have been:

1. Current Year QREs: $5,000,000
2. Base Amount: $2,100,000
3. Incremental Excess: $2,900,000
4. Credit Calculation: 10% of $2,900,000 = $290,000

The application of Directive 02-15 resulted in an additional $80,000 in tax savings for TechNexus Inc. in a single tax year.1

Statutory Limitations and Carryforward Provisions

Even when a credit is correctly calculated and inclusive of all health insurance premiums, its immediate utility is governed by several “floors” and “ceilings” within the Massachusetts tax code.

The Minimum Excise Floor

The Research Credit cannot be used to reduce a corporation’s tax liability below the minimum corporate excise, which is currently set at $456.1 This ensures that every corporation pays a baseline amount to support state infrastructure, regardless of their level of innovation spending.

The 75% Liability Limitation

A more significant restriction is found in the “75% rule.” The credit is limited to:

• 100% of the first $25,000 of corporate excise due.
• 75% of any corporate excise due in excess of $25,000.1

For large-cap companies with high excise liabilities, this rule can result in a significant portion of the credit being disallowed in the current year. However, the Commonwealth provides generous carryforward provisions to ensure these benefits are not permanently lost.

This bifurcated carryforward system—allowing indefinite carryover for credits that were “earned” but capped by the 75% rule—is a unique feature of the Massachusetts code that supports long-term industrial stability.1

Financial Institution Eligibility: TIR 25-3

A recent and major development in Massachusetts tax law involves the eligibility of financial institutions to claim the Research Credit. Historically, the Department of Revenue argued that the § 38M credit was only available to “business corporations” taxed under § 39, and not “financial institutions” taxed under § 2.22

However, the Appellate Tax Board decision in State Street Corporation v. Commissioner of Revenue overturned this position. The Board held that the statutory language of § 38M did not explicitly exclude financial institutions. Following this decision, the DOR issued TIR 25-3, which officially recognizes that all business corporations subject to an excise under M.G.L. c. 63—including financial institutions—may claim the research credit.1

For the banking and financial services sector in Massachusetts, this opens a significant opportunity to include health insurance premiums for software developers, cybersecurity experts, and fintech researchers in their R&D claims. As financial institutions calculate their excise at a rate of 9% of net income, the ability to offset this with R&D credits represents a substantial fiscal benefit.22

Compliance, Audits, and Documentation Best Practices

Because the inclusion of health insurance premiums in an R&D claim relies on administrative guidance (Directive 02-15) rather than explicit statutory language for every detail, it is a frequent focal point for Department of Revenue audits. Compliance requires a rigorous approach to documentation.

Substantiating the “Qualifying” Expenditure

To successfully defend the inclusion of health premiums, a taxpayer must maintain:

• Insurance Invoices: Monthly statements from the carrier showing the total premium and the employer’s portion paid.14
• W-2 and Payroll Registers: To reconcile the premiums with individual employees who are identified as performing qualified research.23
• Form 1099-HC: Copies of the state insurance reporting forms to prove the coverage met MCC standards.9

Demonstrating Research Activity

The DOR uses the federal four-part test to evaluate research activities. For every employee whose premiums are included in the credit base, the company should have:

1. Project Descriptions: High-level summaries of the technical challenges being addressed.
2. Time Tracking: Contemporaneous logs or project-based allocations that show the percentage of time each employee dedicated to the qualified task.14
3. Technical Evidence: Designs, prototypes, test logs, or emails that demonstrate a “process of experimentation” to “eliminate uncertainty”.13

Common Audit Pitfalls

Taxpayers often run into trouble when they attempt to include “support staff” premiums without sufficient evidence. While Directive 02-15 allows for the inclusion of premiums for those in “direct supervision” or “direct support” of research, the burden of proof is high. For example, the premiums for a HR manager are generally not includable, even if they exclusively hire R&D staff, as this is considered an indirect administrative cost rather than “direct support”.1

Economic Impact and Statistical Overview

The Research Credit is a major line item in the Massachusetts Tax Expenditure Budget. It represents a deliberate decision by the legislature to forgo current revenue in exchange for future economic growth and job retention.

Tax Expenditure Data

According to the FY 2025 Tax Expenditure Budget and related fiscal reports, the Commonwealth’s commitment to these credits is substantial:

• Total Corporate Excise Revenue: Projected at approximately $4.5 billion for FY 2025.24
• Research Credit Cost: The state typically “spends” between $350 million and $400 million annually in foregone revenue through the § 38M credit.2
• Small Business Health Credit: While a smaller program, it targets the most vulnerable segment of the economy, providing roughly $10 million to $15 million in direct relief.25

The growth in these expenditures reflects the increasing cost of technical labor and the rising premiums for high-quality health insurance in the New England region. The inclusion of premiums as a wage component accounts for an estimated 8% to 12% of the total value of the R&D credits claimed in the state.

Comparison with Federal and Other State Credits

The treatment of health insurance premiums as R&D wages is a point of divergence between Massachusetts and other jurisdictions.

Federal Comparison

At the federal level, IRC § 41(b) and the associated Treasury Regulations are more restrictive regarding what constitutes “wages.” While certain taxable benefits might be included, employer-paid health insurance premiums (which are typically excluded from an employee’s gross income under IRC § 106) are often excluded from the federal R&D wage base. Massachusetts Directive 02-15 thus provides a “state-only” enhancement that can make the Massachusetts credit more valuable on a per-dollar-spent basis than the federal equivalent in some scenarios.1

Other States

While many states simply “piggyback” on the federal definition of QREs, Massachusetts’ proactive administrative guidance sets it apart. States like Connecticut offer high incremental rates (up to 20%) but have different rules for small business credit exchanges and non-incremental options.27 Massachusetts remains competitive by offering the indefinite carryover for the 75% rule and the unique “Directive 02-15” expansion of the wage base.

Strategic Planning for Small and Mid-Sized Businesses

For businesses with fewer than 50 employees, the interaction between § 38M (R&D) and § 38X (Small Business Health Credit) requires careful strategic analysis.

Scenario A: The High-Growth Startup

A startup with rapidly increasing R&D spending should prioritize the § 38M Research Credit. Because the R&D credit is incremental, the high growth in spending will generate a significant credit. Including health premiums in the R&D base (per Directive 02-15) effectively increases the “10% reward” for every new dollar spent on insurance for research staff.

Scenario B: The Steady-State Laboratory

A small lab with consistent, flat R&D spending might find more value in the standalone § 38X Small Business Health Insurance Credit. This credit offers a 20% flat benefit on premiums in the first year, which is significantly higher than the 10% incremental benefit offered by the R&D credit.4 However, the business must ensure they meet the 50% contribution requirement and have no more than 50 FTEs.5

Coordination of Credits

It is vital to avoid “double dipping.” If a business claims the standalone credit for a specific premium dollar, they must subtract that amount from their “wages” when calculating the R&D credit. Most businesses find it simplest to allocate premiums for research staff to the R&D credit and premiums for administrative staff to the Small Business Health Credit, provided all other eligibility criteria are met.28

Conclusion

The Massachusetts tax landscape offers a robust and multi-faceted support system for businesses that invest in both innovation and the well-being of their workforce. The Qualifying Health Insurance Premium Expenditure Credit, when viewed through the lens of Department of Revenue Directive 02-15 and M.G.L. c. 63, § 38M, serves as a critical bridge between two of the Commonwealth’s most important policy goals: maintaining a global lead in research and ensuring residents have access to high-quality healthcare.

By allowing the reclassification of employer-paid premiums as qualified research wages, Massachusetts provides a significant fiscal advantage to research-intensive firms. This policy recognizes that in a competitive labor market like the one found in the Greater Boston area, comprehensive benefits are an inseparable part of the investment required to push the boundaries of science and technology. Whether a business is a small software startup utilizing the Alternative Simplified Credit or a global life sciences leader seeking refundable offsets through the MLSC, the strategic inclusion of health insurance premiums remains a cornerstone of a sophisticated Massachusetts tax strategy. As the state continues to refine its guidance—demonstrated by the expansion of credit eligibility to financial institutions—taxpayers must remain vigilant in their documentation and allocation practices to ensure they maximize these valuable incentives while remaining in full compliance with the Department of Revenue’s rigorous standards.

R&D Tax Credit Preparation Services

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed provides state and federal R&D tax credit preparation and audit services to all 50 states.

If you have any questions or need further assistance, please call or email our CEO, Damian Smyth on (800) 986-4725.
Feel free to book a quick teleconference with one of our national R&D tax credit specialists at a time that is convenient for you.

R&D Tax Credit Audit Advisory Services

creditARMOR is a sophisticated R&D tax credit insurance and AI-driven risk management platform. It mitigates audit exposure by covering defense expenses, including CPA, tax attorney, and specialist consultant fees—delivering robust, compliant support for R&D credit claims. Click here for more information about R&D tax credit management and implementation.

Our Fees

Swanson Reed offers R&D tax credit preparation and audit services at our hourly rates of between $195 – $395 per hour. We are also able offer fixed fees and success fees in special circumstances. Learn more at https://www.swansonreed.com/about-us/research-tax-credit-consulting/our-fees/